Articles

Pembrolizumab, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 2 Study

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Daratumumab plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of the GEN503 Study

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Dose-Finding Phase 2 Trial of Single-Agent Isatuximab in Relapsed/Refractory Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

ASH 2015 - Multiple Myeloma

Conference Correspondent

Ixazomib plus Lenalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM): Results of the Phase 3 Tourmaline-MM1 Study

ASH 2015 - Multiple Myeloma

Conference Correspondent

Carfilzomib plus Filanesib versus Carfilzomib in Patients with Advanced Multiple Myeloma

ASH 2015 - Multiple Myeloma

Conference Correspondent

Subgroup Analysis of the ENDEAVOR Study of Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Patients with Relapsed MM

ASH 2015 - Multiple Myeloma

Conference Correspondent

Subgroup Analysis Based on Cytogenetic Risk Status: Carfilzomib / Lenalidomide / Dexamethasone versus Lenalidomide / Dexamethasone (ASPIRE Study)

ASH 2015 - Multiple Myeloma

Conference Correspondent

Lenalidomide Maintenance in Patients with Relapsed DLBCL Who Cannot Be Treated with Consolidative Transplantation

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Page 179 of 329